Literature DB >> 33686477

Human pluripotent stem cell-based cardiovascular disease modeling and drug discovery.

Ge Liu1,2, Zhun Liu1,2, Nan Cao3,4.   

Abstract

Heart diseases are prevalent worldwide and account for the highest mortality than any other illness. Although investment in drug discovery and development has increased, the amount of drug approvals has seen a progressive decline. Moreover, adverse side effects to the heart have become the most common reasons for preclinical project cessation, partly due to the lack of suitable humanized preclinical models. Human pluripotent stem cells (hPSCs) have emerged as a powerful non-animal platform to model heart disease, to screen for novel drugs, and to test drug cardiotoxicity in a high-throughput and cost-effective manner. Here, we review and discuss recent breakthroughs in the development of cardiovascular modeling and their current and future applications of hPSC-based drug discovery and testing.

Entities:  

Keywords:  Cardiac disease model; Cardiovascular disease; Drug discovery; hPSCs

Mesh:

Year:  2021        PMID: 33686477     DOI: 10.1007/s00424-021-02542-1

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  76 in total

1.  Trial watch: phase II and phase III attrition rates 2011-2012.

Authors:  John Arrowsmith; Philip Miller
Journal:  Nat Rev Drug Discov       Date:  2013-08       Impact factor: 84.694

2.  Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association.

Authors:  Emelia J Benjamin; Paul Muntner; Alvaro Alonso; Marcio S Bittencourt; Clifton W Callaway; April P Carson; Alanna M Chamberlain; Alexander R Chang; Susan Cheng; Sandeep R Das; Francesca N Delling; Luc Djousse; Mitchell S V Elkind; Jane F Ferguson; Myriam Fornage; Lori Chaffin Jordan; Sadiya S Khan; Brett M Kissela; Kristen L Knutson; Tak W Kwan; Daniel T Lackland; Tené T Lewis; Judith H Lichtman; Chris T Longenecker; Matthew Shane Loop; Pamela L Lutsey; Seth S Martin; Kunihiro Matsushita; Andrew E Moran; Michael E Mussolino; Martin O'Flaherty; Ambarish Pandey; Amanda M Perak; Wayne D Rosamond; Gregory A Roth; Uchechukwu K A Sampson; Gary M Satou; Emily B Schroeder; Svati H Shah; Nicole L Spartano; Andrew Stokes; David L Tirschwell; Connie W Tsao; Mintu P Turakhia; Lisa B VanWagner; John T Wilkins; Sally S Wong; Salim S Virani
Journal:  Circulation       Date:  2019-03-05       Impact factor: 29.690

3.  The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress.

Authors:  Thomas Colatsky; Bernard Fermini; Gary Gintant; Jennifer B Pierson; Philip Sager; Yuko Sekino; David G Strauss; Norman Stockbridge
Journal:  J Pharmacol Toxicol Methods       Date:  2016-06-07       Impact factor: 1.950

Review 4.  Cardiomyopathies: An Overview.

Authors:  Eugene Braunwald
Journal:  Circ Res       Date:  2017-09-15       Impact factor: 17.367

Review 5.  Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association.

Authors:  Charles Antzelevitch; Pedro Brugada; Martin Borggrefe; Josep Brugada; Ramon Brugada; Domenico Corrado; Ihor Gussak; Herve LeMarec; Koonlawee Nademanee; Andres Ricardo Perez Riera; Wataru Shimizu; Eric Schulze-Bahr; Hanno Tan; Arthur Wilde
Journal:  Circulation       Date:  2005-01-17       Impact factor: 29.690

6.  Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity.

Authors:  Paul W Burridge; Yong Fuga Li; Elena Matsa; Haodi Wu; Sang-Ging Ong; Arun Sharma; Alexandra Holmström; Alex C Chang; Michael J Coronado; Antje D Ebert; Joshua W Knowles; Melinda L Telli; Ronald M Witteles; Helen M Blau; Daniel Bernstein; Russ B Altman; Joseph C Wu
Journal:  Nat Med       Date:  2016-04-18       Impact factor: 53.440

7.  Wnt Activation and Reduced Cell-Cell Contact Synergistically Induce Massive Expansion of Functional Human iPSC-Derived Cardiomyocytes.

Authors:  Jan W Buikema; Soah Lee; William R Goodyer; Renee G Maas; Orlando Chirikian; Guang Li; Yi Miao; Sharon L Paige; Daniel Lee; Haodi Wu; David T Paik; Siyeon Rhee; Lei Tian; Francisco X Galdos; Nazan Puluca; Benjamin Beyersdorf; James Hu; Aimee Beck; Sneha Venkamatran; Srilatha Swami; Paul Wijnker; Maike Schuldt; Larissa M Dorsch; Alain van Mil; Kristy Red-Horse; Joy Y Wu; Caroline Geisen; Michael Hesse; Vahid Serpooshan; Stefan Jovinge; Bernd K Fleischmann; Pieter A Doevendans; Jolanda van der Velden; K Christopher Garcia; Joseph C Wu; Joost P G Sluijter; Sean M Wu
Journal:  Cell Stem Cell       Date:  2020-07-02       Impact factor: 24.633

Review 8.  Short QT interval in clinical practice.

Authors:  Preben Bjerregaard; Hari Nallapaneni; Ihor Gussak
Journal:  J Electrocardiol       Date:  2010-07-27       Impact factor: 1.438

9.  Lipophilic beta-adrenoceptor antagonists stimulate cholesterol biosynthesis in human skin fibroblasts.

Authors:  A Corsini; F Bernini; G Cighetti; M Soma; G Galli; R Fumagalli
Journal:  Biochem Pharmacol       Date:  1987-06-15       Impact factor: 5.858

10.  A new paradigm for drug-induced torsadogenic risk assessment using human iPS cell-derived cardiomyocytes.

Authors:  Hiroyuki Ando; Takashi Yoshinaga; Wataru Yamamoto; Keiichi Asakura; Takaaki Uda; Tomohiko Taniguchi; Atsuko Ojima; Raku Shinkyo; Kiyomi Kikuchi; Tomoharu Osada; Seiji Hayashi; Chieko Kasai; Norimasa Miyamoto; Hiroyuki Tashibu; Daiju Yamazaki; Atsushi Sugiyama; Yasunari Kanda; Kohei Sawada; Yuko Sekino
Journal:  J Pharmacol Toxicol Methods       Date:  2016-12-10       Impact factor: 1.950

View more
  2 in total

Review 1.  Assessing Drug-Induced Mitochondrial Toxicity in Cardiomyocytes: Implications for Preclinical Cardiac Safety Evaluation.

Authors:  Xiaoli Tang; Zengwu Wang; Shengshou Hu; Bingying Zhou
Journal:  Pharmaceutics       Date:  2022-06-21       Impact factor: 6.525

2.  Investigating and Resolving Cardiotoxicity Induced by COVID-19 Treatments using Human Pluripotent Stem Cell-Derived Cardiomyocytes and Engineered Heart Tissues.

Authors:  He Xu; Ge Liu; Jixing Gong; Ying Zhang; Shanshan Gu; Zhongjun Wan; Pengcheng Yang; Yage Nie; Yinghan Wang; Zhan-Peng Huang; Guanzheng Luo; Zhongyan Chen; Donghui Zhang; Nan Cao
Journal:  Adv Sci (Weinh)       Date:  2022-09-02       Impact factor: 17.521

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.